Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes

Inclusion Criteria: * Age 18 to 80 years old inclusive * Generally in good health, as determined by the investigator * Living in the United States with no plans to move outside the United States during the study * Diagnosis of T1D for at least 12 months * Currently using a Tandem pump * Current Dexcom CGM user * HbA1c \<9.0% in the last 6 months. * Willing to implement and adhere to pump alert/alarm settings on a study-provided pump as instructed during the study * Willing to wear each investigational infusion set for up to 7 days during each of the wear periods in the study * Willing to perform blood ketone and blood glucose (fingerstick) measurements as directed using provided ketone and blood glucose meters and strips * If using Tandem Mobi, has a compatible cellular phone that can run the Tandem Mobi Mobile App * BMI in the range 18-35 kg/m2, both inclusive * Currently using one of the following insulins with no expectation of a need to change insulin type during the study: 1. Humalog™ (or generic insulin lispro) 2. NovoLog™ (or generic insulin aspart) * Willing to change insulin cartridge every 48-72 hours, as recommended by patient's healthcare provider during the study * Has the ability to understand and comply with protocol procedures and to provide informed consent Exclusion Criteria: * Concurrent use of any non-insulin glucose-lowering agent, other than metformin (for example, GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas) * Female subject is pregnant, planning to become pregnant, or not using adequate method of contraception * Episodes of severe hypoglycemia in the last 6 months resulting in: 1. Medical Assistance (i.e., paramedics, hospital evaluation or hospitalization) 2. Loss of consciousness 3. Seizures * One or more episodes of diabetic ketoacidosis (DKA) in the last 6 months requiring hospitalization * Currently on a ketogenic or low-carbohydrate diet of less than 60 grams of carbohydrates per day, or intending to begin one during the study period * Known history of any of the following conditions: 1. Cushing's Disease 2. Adrenal insufficiency 3. Pancreatic islet cell tumor 4. Insulinoma 5. Lipodystrophy 6. Extensive lipohypertrophy, as assessed by the investigator * Undergoing treatment with systemic oral or intravenous corticosteroids, at or within the last 8 weeks from screening. Inhaled glucocorticoids are allowed. * Significant history of any of the following, that in the opinion of the investigator would compromise safety or successful study participation: 1. Alcoholism 2. Drug abuse * Significant acute or chronic illness, that in the opinion of the investigator might interfere with safety or integrity of study results * Current participation in another clinical drug or device study * Immediate family member (spouse, biological or legal guardian, child, sibling, parent) who is a study site personnel directly affiliated with this study or who is an employee of Tandem Diabetes Care